Dr. Ryan Matthew Meeker, DNP, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1700 S Tamiami Trl, Sarasota, FL 34239 Phone: 614-557-1380 |
Grace Nichols, CRNA Nurse Anesthetist, Certified Registered Medicare: Medicare Enrolled Practice Location: 1700 S Tamiami Trl, Sarasota, FL 34239 Phone: 941-917-8720 Fax: 941-917-1875 |
Pamela Barger, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 1261 S Tamiami Trl, Sarasota, FL 34239 Phone: 941-366-2366 Fax: 941-366-3123 |
News Archive
Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).
Patients who report having a regular doctor either at a community health center or at the physician's office report receiving better quality health care, and have a better health care experience, than patients who have a regular place of care, but lack an established physician relationship. The findings are part of a study published in the May Journal of Health Care for the Poor and Underserved, and authored by Anne Beal, MD, MPH, head of the Aetna Foundation, and Susan Hernandez, MPA, formerly of The Commonwealth Fund.
The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected.
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has entered into a joint technology development and marketing agreement with LinaTech, a leading manufacturer of medical devices and software for treating cancer with radiotherapy.
In a recent study, scientists from the Institute for Cancer Research at MedUni Vienna have shown that the growth factor receptor FGFR3 increases the rate of growth and aggressiveness of hepatocellular carcinomas (liver cell cancer). Inhibition of this receptor could be a new and effective way of treating patients.
› Verified 1 days ago